With mounting interest from biotechs, Big Pharma, and the federal government, research on rare diseases is burgeoning.
Bio Business
Most Recent
Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.
Biotech companies hope to turn the practice of finding novel uses for existing compounds into big business.
The debate over genetically engineered crops rages on, but other technologies offer new hope for sustainable farming.
The surprising results when drug development and altruism collide
Subjects
- biobusiness
- biotech
- business
- cancer
- cell & molecular biology
- clinical trials
- disease/medicine
- drug development
- FDA
- regulation
Sub Categories
- Bio Business
- Capsule Reviews
- Careers
- Contributors
- Critic At Large
- Editorial
- Features
- Foundations
- Lab Tools
- Modus Operandi
- Notebook
- Profile
- Reading Frames
- Scientist to Watch
- Speaking of Science
- The Literature
- Thought Experiment
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
